Goldman Sachs
GNMX

Goldman Sachs’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Goldman Sachs’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-30,960
Closed -$38K – 5880
2018
Q3 		$38K Sell
30,960
-6,542
-17% -$7.31K ﹤0.01% 5334
2018
Q2 		$42K Sell
37,502
-149
-0.4% -$226 ﹤0.01% 5400
2018
Q1 		$76K Sell
37,651
-10,203
-21% -$19.2K ﹤0.01% 5368
2017
Q4 		$57K Sell
47,854
-40,564
-46% -$55.4K ﹤0.01% 5916
2017
Q3 		$111K Sell
88,418
-305,309
-78% -$390K ﹤0.01% 6019
2017
Q2 		$524K Buy
393,727
+181,042
+85% +$262K ﹤0.01% 5059
2017
Q1 		$396K Buy
212,685
+194,507
+1,070% +$880K ﹤0.01% 5231
2016
Q4 		$94K Sell
18,178
-5,155
-22% -$27.1K ﹤0.01% 6172
2016
Q3 		$130K Buy
23,333
+6,641
+40% +$37.9K ﹤0.01% 6093
2016
Q2 		$93K Buy
16,692
+1,674
+11% +$8.79K ﹤0.01% 6165
2016
Q1 		$66K Buy
15,018
+1,786
+13% +$7.35K ﹤0.01% 6289
2015
Q4 		$80K Sell
13,232
-709
-5% -$4.81K ﹤0.01% 6297
2015
Q3 		$109K Buy
+13,941
New +$108K ﹤0.01% 6431
2015
Q2 		– Sell
-21,862
Closed -$176K – 7541
2015
Q1 		$176K Buy
+21,862
New +$165K ﹤0.01% 6110

Other funds holding GNMX

AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $640M AUM 26.68% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Goldman Sachs's GNMX Position: Q4 2018 in Review

Goldman Sachs sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2018, closing a stake of 30,960 shares — an estimated $38K sold.

Goldman Sachs first reported a position in GNMX in Q1 2015 and held it in 14 quarters. The position peaked at $524K in Q2 2017. 38 funds tracked by Wall St. Rank hold GNMX as of Q4 2018.

  • Goldman Sachs reported no remaining Aevi Genomic Medicine Inc position as of Q4 2018 after selling out during the quarter.
  • Goldman Sachs sold 30,960 Aevi Genomic Medicine Inc shares in Q4 2018, an estimated $38K.
  • Goldman Sachs first reported a position in Aevi Genomic Medicine Inc in Q1 2015 and held it in 14 quarters.
  • Goldman Sachs's Aevi Genomic Medicine Inc position peaked at $524K in Q2 2017.
  • 38 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.